COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg

Detalles Bibliográficos
Autores principales: Renner, Andreas, Marth, Katharina, Patocka, Karin, Idzko, Marco, Pohl, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569753/
https://www.ncbi.nlm.nih.gov/pubmed/33257916
http://dx.doi.org/10.1183/23120541.00457-2020
_version_ 1783596791563812864
author Renner, Andreas
Marth, Katharina
Patocka, Karin
Idzko, Marco
Pohl, Wolfgang
author_facet Renner, Andreas
Marth, Katharina
Patocka, Karin
Idzko, Marco
Pohl, Wolfgang
author_sort Renner, Andreas
collection PubMed
description Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg
format Online
Article
Text
id pubmed-7569753
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-75697532020-10-20 COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth Renner, Andreas Marth, Katharina Patocka, Karin Idzko, Marco Pohl, Wolfgang ERJ Open Res Original Research Letters Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg European Respiratory Society 2020-11-02 /pmc/articles/PMC7569753/ /pubmed/33257916 http://dx.doi.org/10.1183/23120541.00457-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Original Research Letters
Renner, Andreas
Marth, Katharina
Patocka, Karin
Idzko, Marco
Pohl, Wolfgang
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title_full COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title_fullStr COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title_full_unstemmed COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title_short COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
title_sort covid-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
topic Original Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569753/
https://www.ncbi.nlm.nih.gov/pubmed/33257916
http://dx.doi.org/10.1183/23120541.00457-2020
work_keys_str_mv AT rennerandreas covid19intwosevereasthmaticsreceivingbenralizumabbustingtheeosinophiliamyth
AT marthkatharina covid19intwosevereasthmaticsreceivingbenralizumabbustingtheeosinophiliamyth
AT patockakarin covid19intwosevereasthmaticsreceivingbenralizumabbustingtheeosinophiliamyth
AT idzkomarco covid19intwosevereasthmaticsreceivingbenralizumabbustingtheeosinophiliamyth
AT pohlwolfgang covid19intwosevereasthmaticsreceivingbenralizumabbustingtheeosinophiliamyth

Ejemplares similares